U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07616089) titled 'Phase I Study of FXS0683 in the Treatment of Blood Tumors' on May 19.
Brief Summary: This is a first-in-human, multicenter, open-label, single-arm Phase I study of FXS0683 in participants with relapsed or refractory hematologic malignancies to evaluate safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity, and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
B-Cell Lymphoma
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia
Intervention:
BIOLOGICAL: FXS0683
FXS0683 is a poten...